Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitaz. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. Methods: Th retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancerwho presented at theSeverance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio mtchin for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. Results: The percentage of subjects who had eve used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivaria onditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% cofidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazoneuse was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients.This suggests that the risk for bladder cancer in Korean diabetic subjects treated ith pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism